Discover and read the best of Twitter Threads about #RheumMadness

Most recents (3)

Time for a massive #RheumMadness thank you thread. This was a HUGE endeavor with so many contributors!

First, massive thanks to ALL OF YOU for participating! This project was always about inspiring collaborative learning. Thanks for playing, learning, debating, and sharing!
Second, huge thanks to the @RheumResearch Foundation for supporting this project through the Clinician Scholar Educator award. All aspiring educators in rheumatology, consider applying for this award! It connects you with an amazing community of educators.
Third, thank you to the fellow/resident members of the #RheumMadness leadership team: @AkiUdupa @GuyKatzMD @didemsayginmd and Allen Witt. It took a special kind of bravery to join this team and educate others on a podcast. You all are amazing!
Read 8 tweets
How well did the #RheumRibbonPanel match #RheumMadness participants' predictions in the #SeronegativeSixteen?

Belimumab for LN vs. Anifrolumab

👩‍⚖️Panel:
Belimumab for LN: 5
Anifrolumab: 2

👩‍💻Participants:
80% picked belimumab for LN

More in 🧵 below 👇 (1/8)
PEXIVAS vs. Avacopan

👩‍⚖️Panel:
PEXIVAS: 3
Avacopan: 4

👩‍💻Participants:
66% picked avacopan

(2/8)
IgG4-RD Classification Criteria vs. RP Subtypes

👩‍⚖️Panel:
IgG4-RD Classification Criteria: 5
RP Subtypes: 2

👩‍💻Participants:
77% picked IgG4-RD Classification Criteria

(3/8)
Read 9 tweets
Still can't get over how good the #RheumMadness scouting reports are.

Common themes:
✅Most teams are convinced they will win their first round match-up (🤔)
✅Everyone is worried about AAV/SLE teams

Are we being blinded by the bright and shiny AAV/SLE trials?

I say yes.

🧵
First, let's acknowledge that these trials (BLISS-LN, TULIP, PEXIVAS, ADVOCATE) are amazing and definitely worthy competitors. But clinical trials aren't new in #Rheumatology and the other teams offer so much to our field.
IgG4-RD Classification Criteria:

✅Disease many in our field don't understand
✅Describe common + rare manifestations
✅Emphasize IgG4-RD 🆚 mimickers

Think it's too rare to win? We don't even know prevalence (likely under-recognized)!

Hence the criteria...
Read 18 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!